European cardiology最新文献_第5页

The Global Burden of Resistant Hypertension and Potential Treatment Options. 难治性高血压的全球负担和潜在治疗方案。

European cardiology Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2023.51

Giacomo Buso, Claudia Agabiti-Rosei, Matteo Lemoli, Federica Corvini, Maria Lorenza Muiesan

{"title":"The Global Burden of Resistant Hypertension and Potential Treatment Options.","authors":"Giacomo Buso, Claudia Agabiti-Rosei, Matteo Lemoli, Federica Corvini, Maria Lorenza Muiesan","doi":"10.15420/ecr.2023.51","DOIUrl":"10.15420/ecr.2023.51","url":null,"abstract":"Resistant hypertension (RH) is defined as systolic blood pressure (SBP) or diastolic blood pressure (DBP) that remains .140 mmHg or .90 mmHg, respectively, despite an appropriate lifestyle and the use of optimal or maximally tolerated doses of a three-drug combination, including a diuretic. This definition encompasses the category of controlled RH, defined as the presence of blood pressure (BP) effectively controlled by four or more antihypertensive agents, as well as refractory hypertension, referred to as uncontrolled BP despite five or more drugs of different classes, including a diuretic. To confirm RH presence, various causes of pseudo-resistant hypertension (such as improper BP measurement techniques and poor medication adherence) and secondary hypertension must be ruled out. Inadequate BP control should be confirmed by out-of-office BP measurement. RH affects about 5% of the hypertensive population and is associated with increased cardiovascular morbidity and mortality. Once RH presence is confirmed, patient evaluation includes identification of contributing factors such as lifestyle issues or interfering drugs/substances and assessment of hypertension-mediated organ damage. Management of RH comprises lifestyle interventions and optimisation of current medication therapy. Additional drugs should be introduced sequentially if BP remains uncontrolled and renal denervation can be considered as an additional treatment option. However, achieving optimal BP control remains challenging in this setting. This review aims to provide an overview of RH, including its epidemiology, pathophysiology, diagnostic work-up, as well as the latest therapeutic developments.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e07"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231817/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessment of the Ischaemic Effects of Myocardial Bridge by Echocardiographic Exercise Stress Test. 通过超声心动图运动负荷试验评估心肌桥的缺血效应

European cardiology Pub Date : 2024-06-19 eCollection Date: 2024-01-01 DOI: 10.15420/ecr.2024.03

Priscilla Lamendola, Nello Cambise, Antonio Di Renzo, Lorenzo Tinti, Antonio De Vita, Saverio Tremamunno, Paola Pastena, Antonietta Belmusto, Rocco Montone, Riccardo Rinaldi, Angelo Villano, Gaetano A Lanza

{"title":"Assessment of the Ischaemic Effects of Myocardial Bridge by Echocardiographic Exercise Stress Test.","authors":"Priscilla Lamendola, Nello Cambise, Antonio Di Renzo, Lorenzo Tinti, Antonio De Vita, Saverio Tremamunno, Paola Pastena, Antonietta Belmusto, Rocco Montone, Riccardo Rinaldi, Angelo Villano, Gaetano A Lanza","doi":"10.15420/ecr.2024.03","DOIUrl":"10.15420/ecr.2024.03","url":null,"abstract":"Background: Detection of myocardial bridge (MB) at angiography suggests it has a role in ischaemic-related symptoms in patients with angina without obstructive coronary artery disease. However, evidence that MB may cause myocardial ischaemia is limited.Methods: We studied 41 patients with MB of the left anterior descending coronary artery and otherwise normal coronary arteries. Fourteen patients with normal coronary arteries and without MB served as controls. All subjects underwent a maximal treadmill exercise stress test (EST) under ECG monitoring. Standard and speckle-tracking echocardiography were performed at baseline and immediately after peak EST.Results: EST duration and peak heart rate and systolic pressure were similar in the two groups. A positive EST (ST-segment depression .1 mm) was found in 18 patients in the MB group (43.9%) and none in the control group (p=0.001). No abnormalities in both left ventricle systolic and diastolic function were found between the two groups in the standard echocardiographic evaluation. Global and segmental (anterior, inferior) longitudinal strain (LS) did not differ at baseline between the groups. There was a small increase in global LS during EST in MB patients but not in the control group (p=0.01). Similar trends were found for regional LSs, with differences being significant for the medium (p=0.028) and apical (p=0.032) anterior segments. No differences in echocardiographic parameters and both global and segmental LSs were observed between MB patients with ischaemic ECG changes during EST versus those without.Conclusion: Our findings do not support the notion that MB results in significant degrees of myocardial ischaemia during maximal myocardial work.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"19 ","pages":"e09"},"PeriodicalIF":0.0,"publicationDate":"2024-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11231813/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141565401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Alcohol and Heart Failure. 酒精与心力衰竭。

European cardiology Pub Date : 2023-12-26 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.12

Debar Rasoul, Ashwin Ajay, Alend Abdullah, Jean Mathew, Benjamin Lee Wei En, Knievel Mashida, Rajiv Sankaranarayanan

{"title":"Alcohol and Heart Failure.","authors":"Debar Rasoul, Ashwin Ajay, Alend Abdullah, Jean Mathew, Benjamin Lee Wei En, Knievel Mashida, Rajiv Sankaranarayanan","doi":"10.15420/ecr.2023.12","DOIUrl":"10.15420/ecr.2023.12","url":null,"abstract":"Alcohol is the most frequently consumed toxic substance in the world and remains a major global public health issue, with one in three adults consuming it worldwide. Alcohol use is a leading risk factor for disease, contributing to over 60 acute and chronic health conditions, with a particularly complex association with cardiovascular disease. Chronic excessive alcohol consumption is associated with a range of cardiac complications, including decreased myocardial contractility, hypertension, arrhythmias, MI and heart failure. However, low-level alcohol consumption is believed to have a protective effect against ischaemic heart disease and diabetes. In most cohort studies, small to moderate amounts of alcohol consumption have not been linked to heart failure, indicating a threshold effect of alcohol with individual (possibly genetic) predisposition rather than a continuous effect of exposure. This review article explores the potential benefits of alcohol on the heart, the association between alcohol use and alcoholic cardiomyopathy and the epidemiology, clinical correlates and management of alcoholic cardiomyopathy.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"18 ","pages":"e65"},"PeriodicalIF":0.0,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10782426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139428085","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Decreased Noise and Identification of Very Low Voltage Signals Using a Novel Electrophysiology Recording System 一种新型电生理记录系统的超低电压信号降噪与识别

European cardiology Pub Date : 2023-10-31 DOI: 10.15420/ecr.2022.37

Josef Kautzner, Petr Peichl, Rune Paamand, Mark D Carlson

{"title":"Decreased Noise and Identification of Very Low Voltage Signals Using a Novel Electrophysiology Recording System","authors":"Josef Kautzner, Petr Peichl, Rune Paamand, Mark D Carlson","doi":"10.15420/ecr.2022.37","DOIUrl":"https://doi.org/10.15420/ecr.2022.37","url":null,"abstract":"Aims: The interpretation of intracardiac electrograms recorded from conventional electrophysiology recording systems is frequently impacted by powerline (50/60 Hz) noise and distortion due to notch filtering. This study compares unipolar electrograms recorded simultaneously from a conventional electrophysiology recording system and one of two 3D mapping systems (control system) with those from a novel system (ECGenius, CathVision ApS) designed to reduce noise without the need for conventional filtering. Methods: Unipolar electrograms were recorded simultaneously from nine consecutive patients undergoing catheter ablation for AF (five patients), atrioventricular nodal re-entrant tachycardia (three patients), or ventricular tachycardia (one patient) over the course of 1 week in 2020. Results: The noise spectral power of the novel system (49–51 Hz) was 6.1 ± 6.2 times lower than that of the control system. Saturation artefact following pacing (duration 97 ± 85 ms) occurred in eight control recordings and no novel system recordings (p<0.001). High frequency, low amplitude signals and fractionated electrograms apparent on unfiltered novel system unipolar recordings were not present on control recordings. Control system notch filtering obscured His bundle electrograms observable without such filtering using the novel system and induced electrogram distortion that was not present on novel system recordings. Signal saturation occurred in five of seven control system recordings but none of the novel system recordings. Conclusion: In this study, novel system recordings exhibited less noise and fewer signal artefacts than the conventional control system and did not require notch filtering that distorted electrograms on control recordings. The novel recording system provided superior electrogram data not apparent with conventional systems.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"2003 13","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135814093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Validating the Prognostic Utility of the ABCD-GENE Score in Asian Patients with Acute Coronary Syndrome Patients on Clopidogrel 验证abcd -基因评分在服用氯吡格雷的亚洲急性冠状动脉综合征患者中的预后效用

European cardiology Pub Date : 2023-10-31 DOI: 10.15420/ecr.2023.27

Cheng Keat Tan, David Bin-Chia Wu, Seh Yi Joseph Tan, Syed Saqib Imran, Xue Ting Wee, Su-Yin Doreen Tan

{"title":"Validating the Prognostic Utility of the ABCD-GENE Score in Asian Patients with Acute Coronary Syndrome Patients on Clopidogrel","authors":"Cheng Keat Tan, David Bin-Chia Wu, Seh Yi Joseph Tan, Syed Saqib Imran, Xue Ting Wee, Su-Yin Doreen Tan","doi":"10.15420/ecr.2023.27","DOIUrl":"https://doi.org/10.15420/ecr.2023.27","url":null,"abstract":"Background: The ABCD-GENE score, which links cytochrome P450 2C19 (CYP2C19) phenotype and high platelet reactivity (HPR) to the risk of major adverse cardiovascular events (MACE) in clopidogrel users, has been validated in white and Japanese populations. The prognostic implications of the score in other Asian cohorts, however, have been largely unchartered. The aim of this study was to validate the prognostic utility of the ABCD-GENE score in a heterogeneous Asian acute coronary syndrome (ACS) cohort. Methods and Results: In this single-centre, retrospective cohort evaluation of 423 ACS patients, the objectives were to characterise the best cut-off score for MACE prognostication by comparing the adjusted 1-year risk of MACE between groups above and below the candidate cut-off scores using Cox regression; and for on-clopidogrel HPR prediction using receiver operating characteristic (ROC) analysis and Youden’s index. In the adjusted Cox model, an ABCD-GENE score cut-off at 10 points significantly predicts the 1-year risk of MACE (adjusted HR 3.771; 95% CI [1.041–13.661]). Female sex, baseline LDL, history of ACS and angiotensin receptor blocker use were additional independent predictors of MACE. On ROC analysis the ideal cut-off for HPR prediction was 7 points. However, that did not independently predict the 1-year risk of MACE (adjusted HR 1.595; 95% CI [0.425–5.989]). Conclusion: The original ABCD-GENE score 10-point cut-off moderately predicts MACE in a heterogeneous, Asian ACS population at 1 year. Additional predictors of MACE were also identified in the present cohort, and these findings should be prospectively validated in larger ACS cohorts.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"51 4","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135869567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology. 新冠肺炎引起的心脏损害：影像学和组织病理学的见解。

European cardiology Pub Date : 2023-10-18 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.02

Valentina O Puntmann, Anastasia Shchendrygina, Carlos Rodriguez Bolanos, Mame Madjiguène Ka, Silvia Valbuena, Andreas Rolf, Felicitas Escher, Eike Nagel

{"title":"Cardiac Involvement Due to COVID-19: Insights from Imaging and Histopathology.","authors":"Valentina O Puntmann, Anastasia Shchendrygina, Carlos Rodriguez Bolanos, Mame Madjiguène Ka, Silvia Valbuena, Andreas Rolf, Felicitas Escher, Eike Nagel","doi":"10.15420/ecr.2023.02","DOIUrl":"10.15420/ecr.2023.02","url":null,"abstract":"Lingering cardiac symptoms are increasingly recognised complications of severe acute respiratory syndrome coronavirus 2 infection, now referred to as post-acute cardiovascular sequelae of COVID-19 (PASC). In the acute phase, cardiac injury is driven by cytokine release and stems from ischaemic and thrombotic complications, resulting in myocardial necrosis. Patients with pre-existing cardiac conditions are particularly vulnerable. Myocarditis due to a direct viral infection is rare. Chronic symptoms relate to either worsening of pre-existing heart disease (PASC - cardiovascular disease) or delayed chronic inflammatory condition due to heterogenous immune dysregulation (PASC - cardiovascular syndrome), the latter affecting a broad segment of previously well people. Both PASC presentations are associated with increased cardiovascular risk, long-term disability and reduced quality of life. The recognition and management of PASC in clinical settings remains a considerable challenge. Sensitive diagnostic methods are needed to detect subtler inflammatory changes that underlie the persistent symptoms in PASC - cardiovascular syndrome, alongside considerable clinical experience in inflammatory cardiac conditions.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"18 ","pages":"e58"},"PeriodicalIF":0.0,"publicationDate":"2023-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71523931","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Percutaneous Left Atrial Appendage Occlusion: What the Practising Physician Should Know. 经皮左心房附件封堵术：执业医师应了解的内容。

European cardiology Pub Date : 2023-09-28 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.18

Pierluigi Merella, Giuseppe Talanas, Giovanni Lorenzoni, Cristiana Denurra, Enrico Atzori, Gavino Casu

引用次数: 0

Tricuspid Regurgitation: Disease State and Advances in Percutaneous Therapy. 三尖瓣返流：疾病现状及经皮治疗进展。

European cardiology Pub Date : 2023-09-28 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.09

Qiuyu Martin Zhu, Natalia Berry

引用次数: 0

The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease. 富含甘油三酯的脂蛋白及其残余物在动脉粥样硬化性心血管疾病中的作用。

European cardiology Pub Date : 2023-09-28 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.16

Mohanad Gabani, Michael D Shapiro, Peter P Toth

{"title":"The Role of Triglyceride-rich Lipoproteins and Their Remnants in Atherosclerotic Cardiovascular Disease.","authors":"Mohanad Gabani, Michael D Shapiro, Peter P Toth","doi":"10.15420/ecr.2023.16","DOIUrl":"https://doi.org/10.15420/ecr.2023.16","url":null,"abstract":"Atherosclerotic cardiovascular disease (ASCVD) is the world's leading cause of death. ASCVD has multiple mediators that therapeutic interventions target, such as dyslipidaemia, hypertension, diabetes and heightened systemic inflammatory tone, among others. LDL cholesterol is one of the most well-studied and established mediators targeted for primary and secondary prevention of ASCVD. However, despite the strength of evidence supporting LDL cholesterol reduction by multiple management strategies, ASCVD events can still recur, even in patients whose LDL cholesterol has been very aggressively reduced. Hypertriglyceridaemia and elevated levels of triglyceride-rich lipoproteins (TRLs) may be key contributors to ASCVD residual risk. Several observational and genetic epidemiological studies have highlighted the causal role of triglycerides within the TRLs and/or their remnant cholesterol in the development and progression of ASCVD. TRLs consist of intestinally derived chylomicrons and hepatically synthesised very LDL. Lifestyle modification has been considered the first line intervention for managing hypertriglyceridaemia. Multiple novel targeted therapies are in development, and have shown efficacy in the preclinical and clinical phases of study in managing hypertriglyceridaemia and elevated TRLs. This comprehensive review provides an overview of the biology, pathogenicity, epidemiology, and genetics of triglycerides and TRLs, and how they impact the risk for ASCVD. In addition, we provide a summary of currently available and novel emerging triglyceride-lowering therapies in development.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"18 ","pages":"e56"},"PeriodicalIF":0.0,"publicationDate":"2023-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2c/ef/ecr-18-e56.PMC10583159.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49686560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Cardiovascular Disease and COVID-19 Vaccines: A Systematic Review and Analysis of Published Cases. 心血管疾病和新冠肺炎疫苗：已发表病例的系统回顾和分析。

European cardiology Pub Date : 2023-09-13 eCollection Date: 2023-01-01 DOI: 10.15420/ecr.2023.01

Abdulrhman Khaity, Ala' Abdala Mohamad Rababah, Omar A Abdelwahab, Khaled Albakri, Rehab Adel Diab, Nada Mostafa Al-Dardery, Mahmoud Abbassy, Balqees M Al-Hanaqtah, Ahmed K Awad, Tamam Mohamad

{"title":"Cardiovascular Disease and COVID-19 Vaccines: A Systematic Review and Analysis of Published Cases.","authors":"Abdulrhman Khaity, Ala' Abdala Mohamad Rababah, Omar A Abdelwahab, Khaled Albakri, Rehab Adel Diab, Nada Mostafa Al-Dardery, Mahmoud Abbassy, Balqees M Al-Hanaqtah, Ahmed K Awad, Tamam Mohamad","doi":"10.15420/ecr.2023.01","DOIUrl":"10.15420/ecr.2023.01","url":null,"abstract":"As vaccination against COVID-19 became more widespread, side-effects that were not initially detected during clinical trials became more prominent. The aim of this systematic review is to discuss reports of adverse cardiovascular events associated with COVID-19 vaccination. Databases were searched from inception up to August 2022 to identify case reports and case series reporting on patients with cardiovascular disease after COVID-19 vaccination. This study assessed 150 published cases. Of these, 109 were case reports and 41 were case series. The majority of patients were male (n=302, 86.6%), with a mean age of 27.6 ± 16.7 years. Of the included patients, 268 (76.6%) had myocarditis, 50 (14.6%) had myopericarditis, 8 (2.3%) had pericarditis, and only 4 (1.1%) had stress-induced cardiomyopathy. Moreover, 30 (8.6%) and 11 (3.1%) were diagnosed with arrhythmia and ischaemic heart disease, respectively. Ultimately, cardiovascular complications after COVID-19 vaccination include myocarditis, myopericarditis, ischaemic heart disease and arrhythmia. The young population, especially young male patients, could be more vulnerable to myocarditis.","PeriodicalId":93994,"journal":{"name":"European cardiology","volume":"18 ","pages":"e54"},"PeriodicalIF":0.0,"publicationDate":"2023-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/c3/f7/ecr-18-e54.PMC10512119.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41158273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0